US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

ATYR PHARMA INC

0.9598

-0.0302-3.05%

Post-market: 0.9557-0.0041-0.43%19:56 EST

Volume:933.50K

Turnover:902.02K

Market Cap:94.05M

PE:-1.14

High:1.01

Open:0.9900

Low:0.9406

Close:0.9900

52wk High:7.29

52wk Low:0.6400

Shares:97.99M

Float Shares:95.97M

Volume Ratio:0.60

T/O Rate:0.97%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.8425

EPS(LYR):-0.8621

ROE:-103.49%

ROA:-49.59%

PB:1.17

PE(LYR):-1.11

Loading ...

Overview Company News Filings

aTyr Pharma Q3 EPS $(0.26) Misses $(0.18) Estimate

aTyr Pharma Inc reports results for the quarter ended September 30 - Earnings Summary

aTyr Pharma reports third quarter 2025 results and updates on efzofitimod studies

Press Release: aTyr Pharma Announces Third Quarter 2025 Results and Provides Corporate Update

aTyr Pharma Inc options imply 21.3% move in share price post-earnings

Calendar of U.S. Earnings Expected in the Week Ahead

aTyr Pharma Reveals EFZO-FIT Study Failure in Investor Call

Investors File Class Action Lawsuit Against aTyr Pharma Inc

aTyr Pharma (ATYR) Faces Legal Scrutiny After Failed Efzofitimod Trial - Can Its Credibility Recover?

Simply Wall St.

aTyr Pharma Inc. Director Paul Schimmel Reports Acquisition of Common Shares

aTyr Pharma reports clinical benefit for efzofitimod across multiple diseases

Piper Sandler healthcare analysts hold an analyst/industry conference call

Leerink Partners downgrades aTyr Pharma (ATYR) to a Hold

Wells Fargo downgrades aTyr Pharma (ATYR) to a Hold

RBC Downgrades aTyr Pharma to Sector Perform From Outperform, Cuts Price Target to $1.50 From $16, Keeps Speculative Risk

MT Newswires Live

aTyr Pharma Inc : H.c. Wainwright Cuts to Neutral From Buy

THOMSON REUTERS

aTyr Pharma Inc : Jefferies Cuts Target Price to $3 From $17

THOMSON REUTERS

Stock Track | ATYR Pharma Rebounds 23% After Hours Following 80% Plunge on Failed Drug Trial

Stock Track | ATYR Pharma Rebounds 5.32% After-Hours Following 80% Plunge on Failed Drug Trial

Crude Oil Rises 1%; Manufacturing Activity in New York Falls In September

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"Tiger Brokers,U.S. stock trading,Hong Kong stock trading,trading U.S. stocks,stock information,stock prices,U.S. stock quotes,U.S. stock trading,Hong Kong stock trading,IPO trading,buying U.S. stocks,global investment","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/ATYR/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"ATYR","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ATYR\",,,,,undefined,":{"symbol":"ATYR","market":"US","secType":"STK","nameCN":"ATYR PHARMA INC","latestPrice":0.9598,"timestamp":1772226000000,"preClose":0.99,"halted":0,"volume":933497,"hourTrading":{"tag":"盘后","latestPrice":0.955701,"preClose":0.9598,"latestTime":"19:56 EST","volume":10028,"amount":9563.815,"timestamp":1772240193828,"change":-0.004099,"changeRate":-0.004271,"amplitude":0.062513},"delay":0,"changeRate":-0.03050505050505051,"floatShares":95966000,"shares":97986634,"eps":-0.842499,"marketStatus":"Market Closed","change":-0.0302,"latestTime":"02-27 16:00:00 EST","open":0.99,"high":1.01,"low":0.9406,"amount":902017.8942151,"amplitude":0.070101,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.842499,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1772442000000},"marketStatusCode":7,"adr":0,"listingDate":1430971200000,"exchange":"NASDAQ","adjPreClose":0.99,"preHourTrading":{"tag":"盘前","latestPrice":0.99,"preClose":0.99,"latestTime":"08:54 EST","volume":8032,"amount":7955.133760000001,"timestamp":1772200455808,"change":0,"changeRate":0,"amplitude":0.004848},"postHourTrading":{"tag":"盘后","latestPrice":0.955701,"preClose":0.9598,"latestTime":"19:56 EST","volume":10028,"amount":9563.815,"timestamp":1772240193828,"change":-0.004099,"changeRate":-0.004271,"amplitude":0.062513},"volumeRatio":0.603166363456612,"impliedVol":1.3247,"impliedVolPercentile":0.3625},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ATYR\",,,,,undefined,":{"symbol":"ATYR","floatShares":95966000,"roa":"-49.59%","roe":"-103.49%","lyrEps":-0.862131,"volumeRatio":0.603166363456612,"shares":97986634,"dividePrice":0,"high":1.01,"amplitude":0.070101,"preClose":0.99,"low":0.9406,"week52Low":0.64,"pbRate":"1.17","psRate":"494.99","week52High":7.2904,"institutionHeld":0,"latestPrice":0.9598,"eps":-0.842499,"divideRate":0,"volume":933497,"delay":0,"ttmEps":-0.842499,"open":0.99,"prevYearClose":0.7831,"prevWeekClose":1.04,"prevMonthClose":0.9598,"prevQuarterClose":0.7831,"fiveDayClose":1.04,"twentyDayClose":0.8506,"sixtyDayClose":0.7411},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ATYR\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-11-06","symbol":"ATYR","fiscalQuarterEnding":"2025/09","expectedEps":-0.2,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1762405200000,"reportTimeType":"post","actualEps":-0.26},{"market":"US","date":"2025-08-07","symbol":"ATYR","fiscalQuarterEnding":"2025/06","expectedEps":-0.18,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1754539200000,"reportTimeType":"post","actualEps":-0.22},{"market":"US","date":"2025-05-07","symbol":"ATYR","fiscalQuarterEnding":"2025/03","expectedEps":-0.19,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1746590400000,"reportTimeType":"post","actualEps":-0.17},{"market":"US","date":"2025-03-13","symbol":"ATYR","fiscalQuarterEnding":"2024/12","expectedEps":-0.23,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1741838400000,"reportTimeType":"post","actualEps":-0.18},{"market":"US","date":"2024-11-07","symbol":"ATYR","fiscalQuarterEnding":"2024/09","expectedEps":-0.22,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1730955600000,"reportTimeType":"post","actualEps":-0.23}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ATYR\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ATYR\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.0909,"buy":0.2727,"hold":0.6364,"sell":0,"strongSell":0,"meanLabel":"HOLD","meanPercent":0.6364,"analysts":11,"updateTime":1763096400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ATYR\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ATYR","date":"2026-02-27","current":-1.13923,"percent":0.803874,"low":-9.277729,"twenty":-5.252075,"median":-3.985607,"eighty":-1.296092,"high":-0.849664,"avg":-3.753983,"sd":2.27635,"marketCap":97006767},"quantilePoints":[{"date":"2024-06-07","current":-2.380173,"twenty":-2.380173,"median":-2.380173,"eighty":-2.380173,"marketCap":128360348},{"date":"2024-06-14","current":-2.367376,"twenty":-2.482546,"median":-2.431359,"eighty":-2.377614,"marketCap":127670239},{"date":"2024-06-21","current":-2.021867,"twenty":-2.446715,"median":-2.367376,"eighty":-2.203579,"marketCap":109037285},{"date":"2024-06-28","current":-1.970681,"twenty":-2.431359,"median":-2.367376,"eighty":-2.111444,"marketCap":106276847},{"date":"2024-07-05","current":-1.970681,"twenty":-2.431359,"median":-2.265003,"eighty":-1.991155,"marketCap":106276847},{"date":"2024-07-12","current":-2.073054,"twenty":-2.39041,"median":-2.092249,"eighty":-1.970681,"marketCap":111797722},{"date":"2024-07-15","current":-2.226613,"twenty":-2.380173,"median":-2.111444,"eighty":-1.970681,"marketCap":120079035},{"date":"2024-08-02","current":-2.495343,"twenty":-2.421122,"median":-2.130639,"eighty":-1.9758,"marketCap":134571333},{"date":"2024-08-09","current":-2.380173,"twenty":-2.403207,"median":-2.265003,"eighty":-1.996274,"marketCap":128360348},{"date":"2024-08-16","current":-2.618312,"twenty":-2.418704,"median":-2.296995,"eighty":-2.001393,"marketCap":151592396},{"date":"2024-08-23","current":-2.448121,"twenty":-2.445503,"median":-2.341783,"eighty":-2.021867,"marketCap":141738890},{"date":"2024-08-30","current":-2.474305,"twenty":-2.468042,"median":-2.373775,"eighty":-2.032104,"marketCap":143254814},{"date":"2024-09-06","current":-2.291023,"twenty":-2.461213,"median":-2.354579,"eighty":-2.073054,"marketCap":132643346},{"date":"2024-09-13","current":-2.448121,"twenty":-2.474305,"median":-2.380173,"eighty":-2.111444,"marketCap":141738890},{"date":"2024-09-20","current":-2.448121,"twenty":-2.474305,"median":-2.399368,"eighty":-2.149834,"marketCap":141738890},{"date":"2024-09-27","current":-2.277931,"twenty":-2.474305,"median":-2.382664,"eighty":-2.226613,"marketCap":131885384},{"date":"2024-10-04","current":-2.277931,"twenty":-2.469749,"median":-2.373775,"eighty":-2.226613,"marketCap":131885384},{"date":"2024-10-11","current":-2.77541,"twenty":-2.474305,"median":-2.382664,"eighty":-2.251748,"marketCap":160687939},{"date":"2024-10-18","current":-3.469263,"twenty":-2.48085,"median":-2.399368,"eighty":-2.251748,"marketCap":200859924},{"date":"2024-10-25","current":-4.241665,"twenty":-2.500488,"median":-2.421938,"eighty":-2.265003,"marketCap":245579681},{"date":"2024-10-31","current":-4.097658,"twenty":-2.555472,"median":-2.431359,"eighty":-2.275241,"marketCap":237242099},{"date":"2024-11-08","current":-4.058383,"twenty":-2.922036,"median":-2.441575,"eighty":-2.277905,"marketCap":234968213},{"date":"2024-11-15","current":-3.78886,"twenty":-3.621287,"median":-2.448121,"eighty":-2.277931,"marketCap":241789871},{"date":"2024-11-22","current":-3.919838,"twenty":-3.629704,"median":-2.448121,"eighty":-2.277931,"marketCap":250148372},{"date":"2024-11-29","current":-4.643298,"twenty":-3.916561,"median":-2.461213,"eighty":-2.285786,"marketCap":296316696},{"date":"2024-12-06","current":-4.301299,"twenty":-4.007344,"median":-2.474305,"eighty":-2.298878,"marketCap":274491670},{"date":"2024-12-13","current":-3.972453,"twenty":-4.100191,"median":-2.474305,"eighty":-2.31136,"marketCap":253506069},{"date":"2024-12-20","current":-4.143453,"twenty":-4.111931,"median":-2.474305,"eighty":-2.3168,"marketCap":264418582},{"date":"2024-12-27","current":-4.95899,"twenty":-4.144489,"median":-2.487396,"eighty":-2.317206,"marketCap":316462874},{"date":"2025-01-03","current":-5.143143,"twenty":-4.229494,"median":-2.500488,"eighty":-2.317206,"marketCap":328214811},{"date":"2025-01-10","current":-4.919528,"twenty":-4.267848,"median":-2.526671,"eighty":-2.317206,"marketCap":313944602},{"date":"2025-01-17","current":-4.932682,"twenty":-4.327606,"median":-2.579037,"eighty":-2.328986,"marketCap":314784026},{"date":"2025-01-24","current":-4.682759,"twenty":-4.341161,"median":-2.768865,"eighty":-2.330035,"marketCap":298834968},{"date":"2025-01-31","current":-4.919528,"twenty":-4.389843,"median":-2.932509,"eighty":-2.330297,"marketCap":313944602},{"date":"2025-02-07","current":-5.090528,"twenty":-4.509129,"median":-3.510289,"eighty":-2.339486,"marketCap":324857115},{"date":"2025-02-14","current":-4.722221,"twenty":-4.606467,"median":-3.575068,"eighty":-2.341783,"marketCap":301353241},{"date":"2025-02-21","current":-5.827142,"twenty":-4.643298,"median":-3.6107,"eighty":-2.357139,"marketCap":371864863},{"date":"2025-02-28","current":-5.090528,"twenty":-4.682759,"median":-3.851618,"eighty":-2.375054,"marketCap":324857115},{"date":"2025-03-07","current":-4.051376,"twenty":-4.682759,"median":-3.972453,"eighty":-2.380173,"marketCap":258542613},{"date":"2025-03-14","current":-5.248373,"twenty":-4.682759,"median":-3.985607,"eighty":-2.381668,"marketCap":334930203},{"date":"2025-03-21","current":-4.929845,"twenty":-4.727483,"median":-3.990774,"eighty":-2.382664,"marketCap":315623450},{"date":"2025-03-28","current":-4.52461,"twenty":-4.75379,"median":-4.035211,"eighty":-2.388848,"marketCap":289679075},{"date":"2025-04-04","current":-3.872289,"twenty":-4.740636,"median":-4.038222,"eighty":-2.400648,"marketCap":247915527},{"date":"2025-04-11","current":-3.802893,"twenty":-4.727483,"median":-4.011134,"eighty":-2.407615,"marketCap":243472596},{"date":"2025-04-17","current":-4.191509,"twenty":-4.722221,"median":-4.035211,"eighty":-2.414083,"marketCap":268353008},{"date":"2025-04-25","current":-4.788314,"twenty":-4.743267,"median":-4.051376,"eighty":-2.421938,"marketCap":306562211},{"date":"2025-05-02","current":-4.635643,"twenty":-4.743267,"median":-4.087671,"eighty":-2.425706,"marketCap":296787764},{"date":"2025-05-09","current":-4.680309,"twenty":-4.75642,"median":-4.108234,"eighty":-2.431359,"marketCap":296787764},{"date":"2025-05-16","current":-4.210769,"twenty":-4.743267,"median":-4.133647,"eighty":-2.432827,"marketCap":267013308},{"date":"2025-05-23","current":-5.333641,"twenty":-4.774836,"median":-4.143453,"eighty":-2.440266,"marketCap":338216856},{"date":"2025-05-30","current":-5.972275,"twenty":-4.816072,"median":-4.149872,"eighty":-2.448121,"marketCap":378713875},{"date":"2025-06-06","current":-7.509205,"twenty":-4.87282,"median":-4.17922,"eighty":-2.448121,"marketCap":476173732},{"date":"2025-06-13","current":-7.621493,"twenty":-4.919528,"median":-4.191509,"eighty":-2.448121,"marketCap":483294087},{"date":"2025-06-20","current":-7.256559,"twenty":-4.932682,"median":-4.241665,"eighty":-2.448121,"marketCap":460152934},{"date":"2025-06-27","current":-7.453062,"twenty":-4.985297,"median":-4.254757,"eighty":-2.448121,"marketCap":472613555},{"date":"2025-07-03","current":-7.453062,"twenty":-5.016231,"median":-4.28094,"eighty":-2.448121,"marketCap":472613555},{"date":"2025-07-11","current":-7.481134,"twenty":-5.080005,"median":-4.302543,"eighty":-2.458595,"marketCap":474393643},{"date":"2025-07-18","current":-8.126785,"twenty":-5.119466,"median":-4.327606,"eighty":-2.461213,"marketCap":515335684},{"date":"2025-07-25","current":-7.796941,"twenty":-5.18655,"median":-4.339852,"eighty":-2.468042,"marketCap":494419641},{"date":"2025-08-01","current":-6.624944,"twenty":-5.237851,"median":-4.345289,"eighty":-2.473394,"marketCap":420100937},{"date":"2025-08-08","current":-7.354811,"twenty":-5.277498,"median":-4.380221,"eighty":-2.474305,"marketCap":466383244},{"date":"2025-08-15","current":-7.337565,"twenty":-5.711388,"median":-4.396173,"eighty":-2.474305,"marketCap":488953303},{"date":"2025-08-22","current":-7.278747,"twenty":-6.338611,"median":-4.472298,"eighty":-2.474305,"marketCap":485033838},{"date":"2025-08-29","current":-7.866928,"twenty":-6.868599,"median":-4.491152,"eighty":-2.474305,"marketCap":524228491},{"date":"2025-09-05","current":-8.043383,"twenty":-7.051635,"median":-4.498606,"eighty":-2.474305,"marketCap":535986887},{"date":"2025-09-12","current":-7.734587,"twenty":-7.202339,"median":-4.538489,"eighty":-2.478232,"marketCap":515409694},{"date":"2025-09-19","current":-1.543977,"twenty":-7.202339,"median":-4.511608,"eighty":-2.474305,"marketCap":102885965},{"date":"2025-09-26","current":-1.313556,"twenty":-7.183573,"median":-4.496851,"eighty":-2.466335,"marketCap":87531460},{"date":"2025-10-03","current":-1.043875,"twenty":-7.138658,"median":-4.477635,"eighty":-2.448121,"marketCap":69560711},{"date":"2025-10-10","current":-1.401343,"twenty":-7.082514,"median":-4.406529,"eighty":-2.442885,"marketCap":93381262},{"date":"2025-10-17","current":-1.470454,"twenty":-7.051635,"median":-4.382946,"eighty":-2.421938,"marketCap":97986634},{"date":"2025-10-24","current":-1.430458,"twenty":-7.012335,"median":-4.346398,"eighty":-2.388848,"marketCap":95321397},{"date":"2025-10-31","current":-1.305763,"twenty":-6.956191,"median":-4.340306,"eighty":-2.375054,"marketCap":87012130},{"date":"2025-11-07","current":-1.004754,"twenty":-6.884883,"median":-4.327606,"eighty":-2.330297,"marketCap":75479104},{"date":"2025-11-14","current":-0.930535,"twenty":-6.741157,"median":-4.315074,"eighty":-2.317206,"marketCap":69903664},{"date":"2025-11-21","current":-0.849664,"twenty":-6.641787,"median":-4.294031,"eighty":-2.285786,"marketCap":63828493},{"date":"2025-11-28","current":-1.018058,"twenty":-6.613715,"median":-4.254757,"eighty":-2.277852,"marketCap":76478567},{"date":"2025-12-05","current":-1.079755,"twenty":-6.467742,"median":-4.247271,"eighty":-2.236667,"marketCap":81113335},{"date":"2025-12-12","current":-0.998232,"twenty":-6.153338,"median":-4.191509,"eighty":-2.08841,"marketCap":74989171},{"date":"2025-12-19","current":-0.9171,"twenty":-5.941396,"median":-4.17922,"eighty":-1.996274,"marketCap":68894402},{"date":"2025-12-26","current":-0.962753,"twenty":-5.88149,"median":-4.159816,"eighty":-1.970681,"marketCap":72323934},{"date":"2026-01-02","current":-1.02145,"twenty":-5.827142,"median":-4.144316,"eighty":-1.58809,"marketCap":76733333},{"date":"2026-01-09","current":-0.945796,"twenty":-5.68245,"median":-4.143453,"eighty":-1.529272,"marketCap":71050108},{"date":"2026-01-16","current":-0.921535,"twenty":-5.590373,"median":-4.115174,"eighty":-1.499863,"marketCap":69227556},{"date":"2026-01-23","current":-0.973579,"twenty":-5.463588,"median":-4.100824,"eighty":-1.470454,"marketCap":73137223},{"date":"2026-01-30","current":-1.109494,"twenty":-5.353291,"median":-4.058383,"eighty":-1.430928,"marketCap":83347430},{"date":"2026-02-06","current":-1.05745,"twenty":-5.277498,"median":-4.044799,"eighty":-1.420105,"marketCap":79437764},{"date":"2026-02-13","current":-1.16206,"twenty":-5.263462,"median":-4.025068,"eighty":-1.381433,"marketCap":87296292},{"date":"2026-02-20","current":-1.369585,"twenty":-5.259961,"median":-3.990774,"eighty":-1.302178,"marketCap":102885965},{"date":"2026-02-27","current":-1.291323,"twenty":-5.252075,"median":-3.985607,"eighty":-1.296092,"marketCap":97006767}],"updateTime":1772373522165},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ATYR\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2581463200","title":"aTyr Pharma Q3 EPS $(0.26) Misses $(0.18) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2581463200","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581463200?lang=en_us&edition=fundamental","pubTime":"2025-11-07 06:00","pubTimestamp":1762466444,"startTime":"0","endTime":"0","summary":"aTyr Pharma Q3 EPS $(0.26) Misses $(0.18) Estimate","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/11/48706203/atyr-pharma-q3-eps-0-26-misses-0-18-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"aTyr Pharma Q3 EPS $(0.26) Misses $(0.18) Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATYR","BK4139"],"gpt_icon":0},{"id":"2581045415","title":"aTyr Pharma Inc reports results for the quarter ended September 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2581045415","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581045415?lang=en_us&edition=fundamental","pubTime":"2025-11-07 05:51","pubTimestamp":1762465878,"startTime":"0","endTime":"0","summary":"aTyr Pharma Inc reports results for the quarter ended September 30 - Earnings SummaryaTyr Pharma Inc ATYR.OQ reported a quarterly adjusted loss of 26 cents per share for the quarter ended September 30","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nL8N3WI3TN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATYR","BK4139"],"gpt_icon":0},{"id":"2581012792","title":"aTyr Pharma reports third quarter 2025 results and updates on efzofitimod studies","url":"https://stock-news.laohu8.com/highlight/detail?id=2581012792","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581012792?lang=en_us&edition=fundamental","pubTime":"2025-11-07 05:01","pubTimestamp":1762462902,"startTime":"0","endTime":"0","summary":"aTyr Pharma Inc. reported cash, cash equivalents, restricted cash, and available-for-sale investments of $92.9 million as of September 30, 2025. Research and development expenses for the third quarter of 2025 were $22.1 million, primarily related to clinical trial and manufacturing costs for the efzofitimod program. General and administrative expenses were $4.8 million for the same period. During the quarter, aTyr Pharma announced results for the Phase 3 EFZO-FIT study of efzofitimod in pulmonary sarcoidosis and plans to meet with the FDA in the first quarter of 2026 to determine next steps. The company also expects to complete enrollment in the Phase 2 EFZO-CONNECT study in systemic sclerosis-related interstitial lung disease in the first half of 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and sho","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nNDL7lDkJB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4112","IE00B3QW5Z07.USD","BK4139","LU0314104364.USD","LU2095319765.USD","NDAQ","LU2210149790.SGD","ATYR","BK4585","IE00B64PRP62.GBP","IE00BGHQF748.EUR","IE00BKPKM429.USD","LU2210150020.SGD"],"gpt_icon":0},{"id":"2581201203","title":"Press Release: aTyr Pharma Announces Third Quarter 2025 Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2581201203","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581201203?lang=en_us&edition=fundamental","pubTime":"2025-11-07 05:01","pubTimestamp":1762462860,"startTime":"0","endTime":"0","summary":"Results reported for Phase 3 EFZO-FIT study of efzofitimod in pulmonary sarcoidosis.Company plans to meet with the FDA to determine path forward for efzofitimod in pulmonary sarcoidosis in the first quarter of 2026.\"Based on the findings from EFZO-FIT, we believe there is drug activity for efzofitimod as evidenced by improvements across multiple clinically relevant efficacy measures. Based on this, coupled with the ongoing high unmet medical need in pulmonary sarcoidosis, we plan to meet with the U.S. Food and Drug Administration  in the first quarter of 2026 to review the results of the study and determine the path forward for efzofitimod in pulmonary sarcoidosis. We plan to provide an update regarding the next steps for the program following that meeting.\". Fatigue Assessment Scale, and complete steroid withdrawal and improvement","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4099","BK4604","BK4139","TM","ATYR","BK4555","BK4585","BK4588","03160"],"gpt_icon":0},{"id":"2581811012","title":"aTyr Pharma Inc options imply 21.3% move in share price post-earnings","url":"https://stock-news.laohu8.com/highlight/detail?id=2581811012","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581811012?lang=en_us&edition=fundamental","pubTime":"2025-11-07 04:35","pubTimestamp":1762461318,"startTime":"0","endTime":"0","summary":"Pre-earnings options volume in aTyr Pharma (ATYR) Inc is normal with calls leading puts 3:2. Implied volatility suggests the market is anticipating...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/atyr-pharma-inc-options-imply-21-3-move-in-share-price-post-earnings-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/atyr-pharma-inc-options-imply-21-3-move-in-share-price-post-earnings-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ATYR","BK4139"],"gpt_icon":0},{"id":"2581065756","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2581065756","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581065756?lang=en_us&edition=fundamental","pubTime":"2025-11-06 19:00","pubTimestamp":1762426800,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.·A-Mark Precs Mtl                                1Q       .60    4:05 PM. ·Achve Life Scncs                                3Q      (.24)   7:30 AM. ·Air Pdts and Chem                                4Q      3.38    6:00 AM. ·Alpha Metall Rsrcs                               3Q      (.52)   7:30 AM. ·Altice USA Inc.                                 3Q      (.06)   7:00 AM","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AMLX","ABNB","ALLO","ALG","ATHM","AGO","ACIW","AVAH","ARLO","BIRD","ATYR","CARL","BIOA","AHR","AURA","AMR","ATUS","ABL","AKAM","AAON","AMBQ","AMN","ADVM","ARHS","ALTG","ASPN","ASTH","APD","AMPH","AAOI","APPN","ADV","AFRM","ALRM","ASMB","BLZE","APLT","ATLC","ALT","AMPX","AORT","GOOS","ACHV","AMRK","OPTU","APYX","AEE","AMTX","ABCL","ACRV"],"gpt_icon":1},{"id":"2581472033","title":"aTyr Pharma Reveals EFZO-FIT Study Failure in Investor Call","url":"https://stock-news.laohu8.com/highlight/detail?id=2581472033","media":"Reuters","labels":["policyRegulatory","dataReport","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581472033?lang=en_us&edition=fundamental","pubTime":"2025-11-05 21:05","pubTimestamp":1762347926,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. aTyr Pharma Inc. published the original content used to generate this news brief via ACCESS Newswire  on November 05, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251105:nNDL4ybXVq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"aTyr Pharma Reveals EFZO-FIT Study Failure in Investor Call","news_tag":"policyRegulatory,dataReport,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATYR","BK4139"],"gpt_icon":0},{"id":"2577068928","title":"Investors File Class Action Lawsuit Against aTyr Pharma Inc","url":"https://stock-news.laohu8.com/highlight/detail?id=2577068928","media":"Reuters","labels":["policyRegulatory","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577068928?lang=en_us&edition=fundamental","pubTime":"2025-10-22 02:44","pubTimestamp":1761072256,"startTime":"0","endTime":"0","summary":"A class action lawsuit has been filed against aTyr Pharma Inc. on behalf of investors who suffered losses due to alleged securities fraud between January 16, 2025, and September 12, 2025. The legal action claims that shareholders were harmed by the company's conduct during this period. The law firm Levi & Korsinsky is leading the case, leveraging its extensive experience in complex securities litigation to represent affected investors. Shareholders who incurred losses have been encouraged to seek more information and consider participating in the lawsuit.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. aTyr Pharma Inc. published the original content used to generate this news brief via ACCESS Newswire  on October 21, 2025, and is solely","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251021:nNDLc3gNGV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ATYR"],"gpt_icon":0},{"id":"2574491904","title":"aTyr Pharma (ATYR) Faces Legal Scrutiny After Failed Efzofitimod Trial - Can Its Credibility Recover?","url":"https://stock-news.laohu8.com/highlight/detail?id=2574491904","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574491904?lang=en_us&edition=fundamental","pubTime":"2025-10-12 15:15","pubTimestamp":1760253333,"startTime":"0","endTime":"0","summary":"aTyr Pharma recently reported that its Phase 3 trial for efzofitimod in pulmonary sarcoidosis failed to meet its primary endpoint, leading to a wave of investor class action lawsuits alleging misleading statements about the drug’s efficacy.\nThere is significant investor scrutiny on the company’s prior disclosures and communications, as legal investigations focus on the statements made during the trial period.\nWe’ll examine how the trial failure and rising legal challenges may impact aTyr...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-atyr/atyr-pharma/news/atyr-pharma-atyr-faces-legal-scrutiny-after-failed-efzofitim","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-atyr/atyr-pharma/news/atyr-pharma-atyr-faces-legal-scrutiny-after-failed-efzofitim","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","ATYR"],"gpt_icon":0},{"id":"2574663190","title":"aTyr Pharma Inc. Director Paul Schimmel Reports Acquisition of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2574663190","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574663190?lang=en_us&edition=fundamental","pubTime":"2025-10-10 06:30","pubTimestamp":1760049058,"startTime":"0","endTime":"0","summary":"Paul Schimmel, Director at aTyr Pharma Inc., reported the acquisition of common shares of aTyr Pharma Inc. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. aTyr Pharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on October 09, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251009:nNDL764Fgd:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"aTyr Pharma Inc. Director Paul Schimmel Reports Acquisition of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATYR","BK4139"],"gpt_icon":0},{"id":"2571082345","title":"aTyr Pharma reports clinical benefit for efzofitimod across multiple diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2571082345","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571082345?lang=en_us&edition=fundamental","pubTime":"2025-09-30 18:20","pubTimestamp":1759227648,"startTime":"0","endTime":"0","summary":"aTyr Pharma (ATYR) presented additional findings from the Phase 3 EFZO-FIT study of efzofitimod in 268 patients with pulmonary sarcoidosis, a major...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/atyr-pharma-reports-clinical-benefit-for-efzofitimod-across-multiple-diseases-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/atyr-pharma-reports-clinical-benefit-for-efzofitimod-across-multiple-diseases-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","ATYR"],"gpt_icon":0},{"id":"2571681873","title":"Piper Sandler healthcare analysts hold an analyst/industry conference call","url":"https://stock-news.laohu8.com/highlight/detail?id=2571681873","media":"TIPRANKS","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571681873?lang=en_us&edition=fundamental","pubTime":"2025-09-30 04:40","pubTimestamp":1759178408,"startTime":"0","endTime":"0","summary":"Healthcare Analysts discuss aTyr Pharma’s (ATYR) opportunity in Pulmonary Sarcoidosis on an Analyst/Industry conference call to be held on Septembe...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/piper-sandler-healthcare-analysts-hold-an-analyst-industry-conference-call-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/piper-sandler-healthcare-analysts-hold-an-analyst-industry-conference-call-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","LABU","XLV","BK4581","ATYR","XBI","BK4585","BK4588"],"gpt_icon":0},{"id":"2568636462","title":"Leerink Partners downgrades aTyr Pharma (ATYR) to a Hold","url":"https://stock-news.laohu8.com/highlight/detail?id=2568636462","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2568636462?lang=en_us&edition=fundamental","pubTime":"2025-09-19 20:35","pubTimestamp":1758285338,"startTime":"0","endTime":"0","summary":"aTyr Pharma received a Hold rating and a $1.00 price target from Leerink Partners analyst Faisal Khurshid on September 16. The company’s shares clo...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/leerink-partners-downgrades-atyr-pharma-atyr-to-a-hold-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/leerink-partners-downgrades-atyr-pharma-atyr-to-a-hold-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ATYR"],"gpt_icon":0},{"id":"2567410182","title":"Wells Fargo downgrades aTyr Pharma (ATYR) to a Hold","url":"https://stock-news.laohu8.com/highlight/detail?id=2567410182","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2567410182?lang=en_us&edition=fundamental","pubTime":"2025-09-16 18:56","pubTimestamp":1758020190,"startTime":"0","endTime":"0","summary":"In a report released today, Derek Archila from Wells Fargo downgraded aTyr Pharma to a Hold, with a price target of $1.00. The company’s shares clo...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/wells-fargo-downgrades-atyr-pharma-atyr-to-a-hold-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/wells-fargo-downgrades-atyr-pharma-atyr-to-a-hold-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ATYR"],"gpt_icon":0},{"id":"2567458106","title":"RBC Downgrades aTyr Pharma to Sector Perform From Outperform, Cuts Price Target to $1.50 From $16, Keeps Speculative Risk","url":"https://stock-news.laohu8.com/highlight/detail?id=2567458106","media":"MT Newswires Live","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2567458106?lang=en_us&edition=fundamental","pubTime":"2025-09-16 18:18","pubTimestamp":1758017913,"startTime":"0","endTime":"0","summary":"aTyr Pharma (ATYR) has an average rating of overweight and mean price target of $9.75, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major b","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","ATYR"],"gpt_icon":0},{"id":"2567417331","title":"aTyr Pharma Inc : H.c. Wainwright Cuts to Neutral From Buy","url":"https://stock-news.laohu8.com/highlight/detail?id=2567417331","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2567417331?lang=en_us&edition=fundamental","pubTime":"2025-09-16 12:13","pubTimestamp":1757996018,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250916:nFWN3V305L:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ATYR"],"gpt_icon":0},{"id":"2567178106","title":"aTyr Pharma Inc : Jefferies Cuts Target Price to $3 From $17","url":"https://stock-news.laohu8.com/highlight/detail?id=2567178106","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2567178106?lang=en_us&edition=fundamental","pubTime":"2025-09-16 11:54","pubTimestamp":1757994886,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250916:nFWN3V20WN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ATYR","BK4139"],"gpt_icon":0},{"id":"1192164700","title":"Stock Track | ATYR Pharma Rebounds 23% After Hours Following 80% Plunge on Failed Drug Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=1192164700","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1192164700?lang=en_us&edition=fundamental","pubTime":"2025-09-16 08:02","pubTimestamp":1757980968,"startTime":"0","endTime":"0","summary":"Shares of ATYR Pharma Inc (ATYR) surged 23.15% in after-hours trading on Monday, staging a partial recovery following a devastating 80% plunge during the regular session. The volatility came after...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["ATYR"],"gpt_icon":0},{"id":"1100430318","title":"Stock Track | ATYR Pharma Rebounds 5.32% After-Hours Following 80% Plunge on Failed Drug Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=1100430318","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1100430318?lang=en_us&edition=fundamental","pubTime":"2025-09-16 05:04","pubTimestamp":1757970260,"startTime":"0","endTime":"0","summary":"ATYR Pharma Inc (ATYR) shares soared 5.32% in after-hours trading on Monday, following a devastating 80% plunge during the regular session. The volatility came after the company announced that its...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["ATYR"],"gpt_icon":0},{"id":"2567095141","title":"Crude Oil Rises 1%; Manufacturing Activity in New York Falls In September","url":"https://stock-news.laohu8.com/highlight/detail?id=2567095141","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2567095141?lang=en_us&edition=fundamental","pubTime":"2025-09-16 02:57","pubTimestamp":1757962669,"startTime":"0","endTime":"0","summary":" ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/markets/market-summary/25/09/47677351/crude-oil-rises-1-manufacturing-activity-in-new-york-falls-in-september","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AIIO","HAIN","QID","QLD","BK4505","BK4585","TQQQ","NQmain","HSDT","BK4082","RNA","BK4139","MNQmain","USAW.SI",".IXIC","PSQ","BK4099","BK4212","ATYR","SQQQ","CHEK","BK4561","NVIW.SI","USJW.SI","TSYW.SI","BK4588"],"gpt_icon":1}],"pageSize":20,"totalPage":3,"pageCount":2,"totalSize":59,"code":"91000000","status":"200"}]}}